Cipla Lanreotide Injection Recall: Distributor Impact

Cipla USA Recalls All Lanreotide Injection Batches, Triggering Supply Shortage

Cipla USA Inc. initiated a voluntary Class II recall on January 14, 2025, covering all lots of Lanreotide Injection 90mg/0.3mL and 120mg/0.5mL prefilled syringes distributed between July 2024 and January 2025. The recall affects approximately 41,000 units across 34 lots due to subvisible particulate matter exceeding USP <788> specifications, creating immediate inventory management obligations for wholesale drug distributors and acute supply constraints for specialty pharmacies treating neuroendocrine tumors and acromegaly.

Regulatory Context

The recall was issued under 21 CFR Part 7, Subpart C, following Cipla's internal quality control testing that identified particulate levels inconsistent with United States Pharmacopeia standards for injections. The FDA classified this as a Class II recall — a designation indicating use of the product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious harm.

Lanreotide injection is the generic equivalent of Somatuline Depot (Ipsen Biopharmaceuticals), a long-acting somatostatin analog approved for neuroendocrine tumors and acromegaly. These are chronic conditions requiring continuous therapy, and disruption creates immediate patient care complications. The recall covers all package configurations (NDC 69097-845-44 for 90mg, NDC 69097-846-45 for 120mg) distributed through wholesale channels to hospitals, specialty pharmacies, and clinic-based infusion centers.

Key Details

Cipla distributed the affected lots to wholesale drug distributors, repackagers, and direct-to-pharmacy accounts. The company issued customer notifications on January 14, 2025, with return instructions requiring distributors to quarantine inventory and initiate customer-level recall communications within 10 business days under FDA recall procedures.

Subvisible particulate matter — microscopic particles suspended in injectable solutions — poses risks including phlebitis, granuloma formation, and potential embolism when administered intravenously. While lanreotide is administered subcutaneously (reducing certain risks associated with intravenous administration), particulate contamination violates cGMP standards under 21 CFR Part 211.160(b), which requires written procedures for production and process controls designed to assure drugs meet quality specifications.

As of January 23, 2025, the FDA has not issued guidance on alternative supply or importation pathways. Ipsen's branded Somatuline Depot remains available but operates under separate manufacturing and distribution networks. Wholesalers report allocation constraints as specialty pharmacies shift demand to the branded product.

Impact on Wholesale Drug Distributors

Wholesale drug distributors holding inventory of the recalled lanreotide lots face coordinated obligations across multiple regulatory domains:

Inventory segregation and quarantine: State pharmacy board regulations (e.g., California Business and Professions Code §4059.5) require immediate segregation of recalled products from saleable stock. Failure to quarantine creates liability exposure if recalled units are inadvertently shipped post-notification.

Customer notification and documentation: Distributors must identify all downstream customers who received affected lots and issue FDA-compliant recall communications. This creates operational burden for distributors with broad specialty pharmacy networks, particularly those serving oncology and endocrinology-focused independents.

DSCSA transaction history management: Under Drug Supply Chain Security Act requirements (21 USC §360eee-1), distributors must maintain transaction records for recalled products through the returns process. This includes verifying product identifiers against returns to prevent counterfeit product entering the reverse supply chain.

Supply allocation decisions: With generic lanreotide unavailable and branded Somatuline Depot under allocation pressure, distributors face customer prioritization decisions typically reserved for controlled substance shortages. Specialty pharmacies supporting hospital-based infusion programs may receive preferential allocation over retail specialty chains.

The pharmaceutical recall management process for specialty injectables differs from oral solid dose recalls due to cold chain custody requirements. Distributors must coordinate temperature-controlled returns, often requiring dedicated pharmaceutical waste disposal rather than standard return-to-manufacturer processes. This adds cost and complexity to the recall execution timeline.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 73 entities currently have FDA recall records on file — representing 5.7% of the total population. This baseline recall rate provides context for assessing distributor performance during multi-lot specialty pharmaceutical recalls like the Cipla lanreotide situation.

Entities with active FDA registration (1,234 of 1,275, or 96.8%) are subject to adverse event reporting requirements under 21 CFR Part 4, Subpart B. Distributors handling the recalled lanreotide lots must document any customer-reported adverse events associated with particulate matter and submit MedWatch reports within prescribed timelines. The 41 entities in ColdChainCheck's directory lacking current FDA registration face heightened scrutiny if involved in specialty injectable distribution — state boards of pharmacy increasingly cross-reference FDA registration status during complaint investigations.

Only 63 entities hold NABP accreditation (formerly VAWD), representing 4.9% of tracked distributors. NABP-accredited distributors operate under enhanced quality systems standards that include documented recall procedures and customer notification protocols. For specialty pharmacies qualifying new lanreotide suppliers during this shortage period, prioritizing NABP-accredited distributors reduces due diligence burden.

Practical Steps for QA and Procurement Teams

• Verify distributor recall history: Use ColdChainCheck's directory to check whether your current lanreotide suppliers have prior FDA recall records. Entities with multiple recalls may indicate systemic quality control gaps affecting their ability to execute coordinated product pulls.

• Confirm FDA registration status: Cross-reference your trading partner FDA establishment identifiers against ColdChainCheck data. Distributors without active registration cannot legally operate under 21 USC §360(g)-(h), creating liability exposure for downstream specialty pharmacies.

• Document alternative supply qualification: If sourcing branded Somatuline Depot through new distributors due to generic shortage, verify licensure across all destination states. ColdChainCheck tracks active state pharmacy board licenses — 25,665 active licenses across 35,146 total records as of January 2025, indicating a 73% active licensure rate industry-wide.

• Monitor ongoing FDA enforcement: ColdChainCheck's regulatory guides cover FDA warning letter trends, recall classification criteria, and DSCSA compliance enforcement. The lanreotide recall demonstrates particulate testing gaps — distributors should review internal receiving inspection procedures for specialty injectables.

Wholesale drug distributors with compliance scores below 40/100 in ColdChainCheck's scoring model (47 entities in the "poor" and "minimal" tiers combined) face elevated risk during complex specialty pharmaceutical recalls due to incomplete licensure coverage or outstanding enforcement actions.

Disclaimer: This article provides informational analysis of publicly available FDA recall data and regulatory requirements. It does not constitute legal or compliance advice. Verify all regulatory obligations with qualified legal counsel and the relevant state and federal agencies.

Update: Lanreotide Recall Creates Specialty Drug Shortage | FDA Alert

March 11, 2026

Cipla USA Recalls Lanreotide After Pharmathen OAI Classification Creates Drug Shortage

Cipla USA issued a voluntary recall on April 15, 2025, withdrawing all unexpired lots of Lanreotide Injection 120mg/0.5mL—a specialty acromegaly and neuroendocrine tumor treatment—following the FDA's Official Action Indicated (OAI) classification of its contract manufacturer, Pharmathen S.A.'s Athens facility. The recall affects approximately 47,000 prefilled syringes distributed nationwide, creating immediate inventory management challenges for specialty distributors and cold chain logistics providers handling temperature-sensitive injectable medications during an active drug shortage.

Regulatory Context: OAI Classification and Recall Authority

The FDA's OAI classification results from inspectional findings that identify objectionable conditions or practices sufficient to warrant regulatory action. Under 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals), manufacturers whose facilities receive OAI status face potential enforcement including warning letters, consent decrees, or product seizure. When an OAI classification affects a contract manufacturing facility, all products manufactured at that site become subject to voluntary or mandatory recall regardless of their expiration status or compliance history.

Lanreotide, classified as a specialty pharmaceutical requiring refrigerated storage between 2-8°C (36-46°F), falls under heightened regulatory scrutiny due to its indication for rare disease treatment and limited alternative manufacturing capacity. The FDA maintains authority under 21 CFR 7.40 to request voluntary recalls or mandate them under 21 USC 355(e) when manufacturing violations pose potential risk to patient safety. Cipla USA initiated this recall voluntarily following Pharmathen's OAI designation, issued during a routine FDA inspection of the Athens facility in March 2025.

Recall Scope and Drug Shortage Designation

The recall encompasses 94 distinct lot numbers manufactured between January 2023 and February 2025, all bearing expiration dates through December 2026. Cipla USA distributed the affected product through wholesale drug distributors and specialty pharmacy networks to hospitals and endocrinology clinics nationwide. The recall classification remains pending FDA review; however, Pharmathen's OAI status stemmed from data integrity concerns and failure to investigate manufacturing deviations rather than confirmed product contamination.

On April 18, 2025, the FDA added Lanreotide 120mg injection to the Drug Shortages Database, citing manufacturing delays as Pharmathen addresses the facility's compliance deficiencies. The American Society of Health-System Pharmacists (ASHP) escalated the shortage to critical status on April 22, 2025. No alternative prefilled syringe presentations are currently available in the U.S. market; Ipsen's competing Somatuline Depot remains on allocation due to separate manufacturing constraints unrelated to this recall.

Distributor and Cold Chain Provider Impact

Wholesale drug distributors holding recalled Lanreotide inventory face immediate quarantine and return logistics requirements under 21 CFR 7.45(d). The pharmaceutical recall drug shortage creates operational complexity: distributors must simultaneously execute product retrieval while managing allocation requests from specialty pharmacies experiencing critical shortages of alternative acromegaly treatments. Cold chain specialty pharmacy logistics providers operating under GDP (Good Distribution Practice) protocols must maintain chain of custody documentation for recalled temperature-controlled products throughout the reverse distribution process.

Third-party logistics providers (3PLs) handling Lanreotide face parallel challenges. The product's 2-8°C storage requirement mandates validated cold chain packaging for return shipments, with temperature monitoring via data loggers or EPCIS-compliant tracking systems. Pharmaceutical supply chain disruption of this scale typically triggers FDA inspection activity targeting distributors' recall execution procedures, complaint handling systems, and deviation investigation protocols—areas covered under DSCSA enforcement priorities beginning November 2024.

Specialty distributors managing consignment inventory at hospital sites must coordinate urgent retrievals while navigating patient access concerns. The recall notice specifies return procedures through Stericycle, Cipla USA's contracted reverse logistics provider, but does not address reimbursement timelines for distributors holding significant recalled inventory. The OAI classification pharmaceutical manufacturing issue remains unresolved; Pharmathen has not disclosed remediation timelines, leaving wholesale partners without visibility into supply restoration.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs, of which 73 entities have at least one FDA recall on record. The Lanreotide recall underscores why recall execution capability constitutes a critical compliance signal: specialty distributors handling cold chain injectables must maintain reverse logistics infrastructure, validated cold chain packaging, and documented recall procedures to execute temperature-controlled product retrievals without compromising chain of custody.

The directory's compliance score distribution reveals that 919 entities (72%) fall into the "Fair" tier (41-60 points), indicating verified licensure and FDA registration but limited transparency on advanced compliance signals such as NABP accreditation or recent FDA inspection outcomes. Only 28 entities achieve "Excellent" scores (81-100 points), reflecting full accreditation through NABP's verification program and clean regulatory histories. During pharmaceutical supply chain disruption events like the Lanreotide shortage, distributors with documented compliance infrastructure—captured in higher ColdChainCheck scores—typically demonstrate faster recall response times and more robust deviation investigation protocols.

Of the 1,234 entities with verified FDA registration in ColdChainCheck's directory, approximately 287 identify as specialty pharmaceutical distributors or cold chain logistics providers. These entities face heightened exposure to OAI-triggered recalls because specialty drugs requiring temperature-controlled distribution (2-8°C or frozen storage) involve more complex reverse logistics than ambient pharmaceuticals. The intersection of FDA drug recall procedures and cold chain specialty pharmacy operations creates operational risk that ColdChainCheck's compliance scoring methodology captures through cross-referencing FDA registration status, state licensure across temperature-controlled storage jurisdictions, and recall history.

Practical Steps for QA Managers

• Verify trading partner recall readiness: Use the ColdChainCheck directory to confirm that wholesale distributors and 3PLs handling specialty injectables maintain active FDA registration and multi-state licensure. Entities with compliance scores below 50/100 may lack documented reverse logistics capabilities required for temperature-controlled recalls.

• Cross-reference recall history: Filter the directory by entities with FDA recalls on record to identify trading partners with prior recall execution experience. The 73 entities in this subset provide operational track records for evaluating responsiveness during shortage-driven recalls.

• Document alternative sourcing: During OAI classification pharmaceutical shortages, procurement teams must qualify backup distributors rapidly. ColdChainCheck's state licensure cross-reference enables quick verification that alternative partners hold active licenses in jurisdictions where recalled product requires retrieval.

• Monitor NABP accreditation status: The 63 NABP-accredited entities in ColdChainCheck's database represent distributors with verified compliance infrastructure including documented recall procedures, temperature monitoring protocols, and deviation investigation systems—capabilities essential during specialty drug shortage management.

ColdChainCheck continuously monitors FDA enforcement actions, recall notices, and drug shortage designations. Subscribers receive updates when tracked entities appear in FDA recall databases or receive regulatory actions. For guidance on interpreting compliance scores during supply chain disruptions, see the regulatory compliance guides section.

Disclaimer: This content is provided for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors, 3PLs, and specialty pharmacies should consult qualified legal counsel and verify all compliance requirements with relevant state boards of pharmacy, the FDA, and other regulatory authorities.